

HEMISPHERX BIOPHARMA INC  
Form 8-K  
March 30, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**March 30, 2016 (March 30, 2016)**

**HEMISPHERX BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**                      **0-27072**              **52-0845822**  
(state or other juris-      (Commission (I.R.S. Employer  
diction of incorporation) File Number) (Identification No.)

**16179103**  
**JFK**  
**Boulevard,**  
**Suite**

**500,  
Philadelphia,  
PA**

(Address  
of  
principal  
executive  
offices)

Registrant's  
telephone number,  
including area code:  
**(215) 988-0080**

**1617 JFK  
Boulevard, Suite  
500, Philadelphia,  
PA 19103**

(Former name or  
former address, if  
changed since last  
report)

Check the  
appropriate box  
below if the Form  
8-K filing is  
intended to  
simultaneously  
satisfy the filing  
obligation of the  
registrant under any  
of the following  
provisions (see  
General Instruction  
A.2. below):

Written  
communications  
pursuant to Rule  
425 under the  
Securities Act (17  
CFR 230.425)

Soliciting material  
pursuant to Rule  
14a-12 under the  
Exchange Act (17  
CFR 240.14a-12)

Pre-commencement  
communications  
pursuant to Rule  
14d-2(b) under the  
Exchange Act (17  
CFR 240.14d-2(b))

Pre-commencement  
communications  
pursuant to Rule  
13e-4(c) under the  
Exchange Act (17  
CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition**

On March 29, 2016, Hemispherx Biopharma, Inc. (the "Company") filed its annual report on Form 10-K for the year ended December 31, 2015 and, thereafter, issued a press release announcing its financial results for the fourth quarter and full year then ended. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

As noted in a prior press release issued on March 22, 2016, the Company will host a conference call at 2:00 p.m. Eastern Daylight Time (EDT) on Wednesday, March 30, 2016 to discuss recent changes to the Company's management and to provide general information regarding the new strategy for the Company's operations.

**Conference Call Information**

Date:	Wednesday, March 30, 2016
Time:	2:00 PM EDT
Dial-in numbers:	800-346-7359 (domestic) 973-528-0008 (international)
Conference number:	27781
Questions:	ir@hemispherx.net by 10:00 AM EDT on Wednesday, March 30, 2016

A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until April 13, 2016 by dialing:

Domestic callers: (800) 332-6854  
International callers: (973) 528-0005  
Conference entry code: 27781

**Item 7.01 Regulation FD Disclosure.**

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated March 29, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX BIOPHARMA,  
INC.

March 30, 2016 By: /s/ Thomas K. Equels  
Thomas K. Equels, President